Efficacy and Safety of AEB071 Versus Tacrolimus in Combination With Mycophenolate Acid Sodium, Basiliximab and Steroids in Preventing Acute Rejection After Kidney Transplantation

You may be eligible if

• Inclusion:
• Male and female patients of any race 18 years or older
• Adult recipients of kidney transplant from a deceased or living donor
• Recipients of a functioning kidney within 24 hours post transplant
• Exclusion:
• Need for medication prohibited by the protocol
• Patients or donors infected with Hepatitis B,C or HIV
• Patients with a history of cancer within last 5 years
• Patients with history of significant cardiac disorder
• Patients of high-risk immunological status